I’ll admit to being surprised initially by the mid-month announcement that Regeneron Pharmaceuticals planned to buy out of bankruptcy most of the assets of 23andMe.

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday.